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Abstract
Background: Cerebrospinal fluid (CSF) may be valuable for exploring protein markers for the
diagnosis of Alzheimer's disease (AD). The prospect of early detection and treatment, to slow
progression, holds hope for aging populations with increased average lifespan. The aim of the
present study was to investigate candidate CSF biological markers in patients with mild cognitive
impairment (MCI) and AD and compare them with age-matched normal control subjects.
Methods: We applied proteomics approaches to analyze CSF samples derived from 27 patients
with AD, 3 subjects with MCI and 30 controls. The AD group was subdivided into three groups by
clinical severity according to clinical dementia rating (CDR), a well known clinical scale for
dementia.
Results: We demonstrated an elevated level of fibrinogen gamma-A chain precursor protein in
CSF from patients with mild cognitive impairment and AD compared to the age-matched normal
subjects. Moreover, its expression was more prominent in the AD group than in the MCI and
correlated with disease severity and progression. In contrast, fibrinogen gamma-A chain precursor
protein was detected very low in the age-matched normal group.
Conclusion: These findings suggest that the CSF level of fibrinogen gamma-A chain precursor may
be a candidate biomarker for AD.
Background
Neurodegenerative diseases are characterized by chronic,
progressive, irreversible deterioration of neurological
function affecting cognition and motor-sensory functions.
Diagnosis of neurodegenerative disease largely depends
on clinical manifestations; patients usually present to cli-
nicians when their symptoms interfere with activities of
daily living (ADL). By the time patients present with these
complaints, nerve cells have already been damaged irre-
versibly and progression of disease may be inevitable. For
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this reason, there is a need for a molecular-based diagnos-
tic marker in biologic fluids that can identify neurodegen-
erative disease at an early or preclinical phase; this
diagnostic marker could be a disease-modifying com-
pound targeted to drug development [1].
Biochemical changes in the brain are well reflected in the
CSF which is in direct contact with the brain extracellular
space. Biomarkers have been discussed as possible diag-
nostic tools but have not been frequently used in research
on the elderly because of the general paucity of supportive
scientific data. However, there is an obvious need for
greater diagnostic specificity and sensitivity across many
diagnoses in the elderly, as well as good targets for thera-
peutic trials. Of the many possible areas for the discovery
of biomarkers, the field of proteomics is especially well
suited for investigation of biomarkers in the CSF which
contains proteins associated with brain functioning under
healthy conditions as well as with several neurodegenera-
tive diseases. Many studies have demonstrated proteins in
CSF associated with neurodegenerative disease using pro-
teomics. Of the many neurodegenerative diseases studied,
Alzheimer's disease (AD) has been most frequently
reported [1-6].
AD, the most common form of dementia, is the most
prevalent neurodegenerative disease and affects nearly
10% of the population after 65 years of age [7]. Like other
neurodegenerative diseases, the diagnosis of AD is based
on clinical findings and progression of the disease
together with exclusion of other causes of dementias; only
the neuropathological findings confirm a definite diagno-
sis. Most of the diagnostic pathological characteristics
include extracellular amyloid plaque and intracellular
neuofibrillary tangle [8]. While some progress has been
made in the search for adequate biomarkers in the elderly,
in particular with AD, much more work is needed before
these potential biomarkers can be reliably used in clinical
practice. Previous studies infrequently have focused on
staging of the clinical phase of a disease and progression
with neuropsychological investigations.
The purpose of our study was to develop a novel biomar-
ker for AD by applying proteomics to CSF samples; our
data demonstrate that fibrinogen gamma-A chain precur-
sor protein is increased in CSF samples from the patient
groups with MCI and AD.
Methods
Patient selection and grouping
During the study period from Oct. 2004 to Sep. 2005, a
total of 60 subjects were enrolled at the Bobath Memorial
Hospital. We applied proteomics approaches to analyze
CSF samples derived from 27 patients with AD, 3 subjects
with MCI and 30 controls. There were 30 individuals
(mean age = 77.7 y, ranging from 76 to 80) with clinically
diagnosed neurodegenerative diseases such as 3 MCIs and
27 ADs and 30 age-matched normal control subjects
(mean age = 73.2 y, ranging from 61 to 95). None of the
patients had other malignancies or active pulmonary dis-
ease. CSF was obtained from 60 subjects before therapy.
All patients and controls were subject to the analysis with
individual consent for the study. The use of CSF samples
was approved by the Ethics Committee of our institution.
The diagnosis of probable AD was made according to cri-
teria proposed by the National Institute of Neurological
and Communicative Disorders and Stroke--Alzheimer's
Disease and Related Disorders Association (NINCDS-
ADRDA) [9] and the diagnosis of mild cognitive impair-
ment was made by Petersen's criteria [10].
Differences in disease progression were evaluated using
the clinical dementia rating (CDR) [11]. Because it is dif-
ficult to differentiate CDR 0.5 with 1 and CDR 3 with 4,
and 5, we arbitrarily subdivided them into three group:
group 1 (CDR 0.5 and 1), group 2 (CDR 2), group 3 (CDR
3, 4 and 5). The subjects were classified according to
whether they were controls with no cognitive deficit group
or they had mild cognitive impairment (MCI). The thirty
controls were defined by both the absence of significant
cognitive impairment and of AD or other significant neu-
ropathology. The patients without dementia, the control
group, consisted of patients with other complaints such as
back pain and headache. Neuropsychological testing was
performed on all participants to confirm their cognitive
status.
CSF samples
CSF was obtained by lumbar puncture from individuals.
The stage of disease at the time of lumbar puncture was
variable. 10 ml of CSF was obtained and aliquoted into
samples of 1 ml each; then they were shipped on dry ice
and stored at -70°C until needed.
Two-dimensional gel electrophoresis
Briefly, 125 µl aliquots of CSF (containing approximately
50 µg of protein) were precipitated overnight at -20°C
using ice-cold ethanol. The resulting protein pellet was
dissolved in 125 µl of 7 M urea, 2 M thiourea, 4% CHAPS,
60 mM dithiothreitol, 0.5% carrier ampholytes and a
trace of bromophenol blue. The sample was then
hydrated directly into commercially available pH 4–7
nonlinear immobilized pH gradient (IPG) isoelectric
focusing gels (Amersham Biosciences, Piscataway, NJ).
The first dimension of separation, isoelectric focusing,
was then performed at 20°C using the IPGphor isoelectric
focusing unit (Amersham Pharmacia Biotec, CA) for a
total of 75 kVh. The IPG gels were equilibrated in solu-
tions containing dithiothreitol for reduction and then
iodoacetamide for alkylation. The second dimension of
separation, polyacrylamide gel electrophoresis, was then
performed using 12 %T acrylamide slab gels. Next, 2 DE
gels were stained with silver nitrate for mass spectrometry
analysis and confirmation of proteins that existed in lowBMC Neurology 2007, 7:14 http://www.biomedcentral.com/1471-2377/7/14
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abundant spots [12]. Gels were fixed overnight in 30%
ethanol, 10% acetic acid and washed with 20% ethanol
for 20 min. The gels were sensitized for 1 min in 0.02%
sodium thiosulfate and then the gels were incubated in
0.2% silver nitrate for 45 min. Development of protein
spots were in 3% potassium carbonate, 0.025% formalde-
hyde, 0.001% sodium thiosulfate and were scanned on a
GS-800 Calibrated Densitometer (Bio-Rad Laboratories,
Seoul, Korea). Gels were run in duplicate and spots were
selected that appeared consistently in all of the runs.
In-gel digestion
We excised 1 mm cutting diameter protein spots to ana-
lyze. In-gel digestion was then performed according to
protocols previously described [13]. Briefly, gel plugs were
destained with solution mix of 30 mM potassium ferricy-
anide and 100 mM sodium thiosulfate by 1:1 (v/v); the
gel plugs were washed 3 times for 15 min in distilled
water. Destained gel plugs were shrank by 50 mM ammo-
nium bicarbonate, acetonitrile and then dried down in a
vacuum centrifuge. The proteins were then reduced and
alkylated using solutions of 10 mM dithiothreitol and 100
mM iodoacetamide. Gel plugs were washed with 50 mM
ammonium bicarbonate and dried with acetonitrile
which were then rehydrated with a solution of trypsin
(sequencing grade; Promega, Madison, WI) (5 µg/ml).
The digestion process was performed overnight at 37°C
and was stopped by addition of 3% formic acid. For some
low-concentration spots, two or three gel plugs were
digested together to increase the peptide yield. Samples
were crystallized onto a MTB AnchorChip TM 600/384
(Bruker Daltonik GmbH, Leipzig, Germany) MALDI plate
using the dried droplet method. For the matrix, a solution
of 20 µg/µl α-cyano-4-hydroxycinnamic acid (CHCA) in
0.1% triflouroacetic acid/ACN (v/v = 70:30) was used.
CHCA matrix solution was diluted 10 times with ethanol/
acetone (v/v = 70:30) and then peptides samples were
diluted 10 times in CHCA matrix solution.
MS analysis
Linear and reflectron MALDI-TOF mass spectra were
acquired on an Ultraflex mass spectrometer (Bruker Dal-
tonik). Positive ion spectra were recorded using alumi-
num sample holders with standard parameter; a nitrogen
laser (λ = 337 nm), 39 ns pulse duration and 20 kV for
accelerating voltage. Peptide mass fingerprint data were
collected in the positive MS reflector mode in the range of
500–4000 mass-to-charge ratio (m/z) using 1000–3000
laser shots for each sample and were calibrated internally
using trypsin autolysis peaks. The spectra were analyzed
using flexAnalysis (Version 2.2, Bruker Daltonik GmbH),
which acts as an interface between the BioTools (Version
2.2, Bruker Daltonik) database containing raw spectra and
a local copy of the Mascot search engine [14]. The MS data
were searched together against a locally stored copy of the
NCBInr human protein database using the Mascot search
engine. The search allowed for up to one missed trypsin
cleavage site, oxidation of methionine, and carbamid-
omethylation of cysteine.
Results
Expression patterns of CSF protein spots in normal, MCI 
and AD
Figure 1 shows 2-DE images of gels from the CSF samples
of normal control, MCI, and AD (group 1, 2, and 3
according to the CDR). On gels loaded with 50 µg of the
CSF sample, 350 spots were detected. A visual comparison
of spot patterns on the 2-DE gels from the CSF samples
changed gradually in MCI and AD compared to normal
controls. Although the individual spot intensities are var-
iable between samples, the spot patterns are very similar.
All CSF samples used in this experiment, to analyze rela-
tive differential expression, contain all proteins including
albumin and IgG.
Identification of a novel candidate protein whose 
expression in CSF is altered relative to normal controls
We analyzed the differential protein expression of AD
patients' CSF samples, to find candidates for AD-associ-
ated proteins; selective protein identification was per-
formed by peptide mass fingerprinting with delayed
extraction-matrix assisted laser desorption/ionization-
Comparison of the 2-DE gels loaded with CSF from a AD  patient Figure 1
Comparison of the 2-DE gels loaded with CSF from a 
AD patient. All gels were loaded with 50 µg CSF proteins 
and the second dimension of separation, polyacrylamide gel 
electrophoresis, was then performed using 12 %T acrylamide 
slab gels. 2-DE gels were silver stained to visualize all pro-
teins.BMC Neurology 2007, 7:14 http://www.biomedcentral.com/1471-2377/7/14
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time of flight-mass spectrometry (DE-MALDI-TOF-MS).
Their identification baseline was noted first, with a high
Mascot score more than 67 points, and second, with a
molecular weight and pI value similar to identified pro-
teins, and finally with a high coverage from identified pro-
tein full sequence.
In total, two over-expressed protein spots were identified
(Figure 2). These two spots corresponding to a molecular
weight of 50 kDa were identified as a fibrinogen gamma-
A chain precursor. The detailed data for the identified pro-
tein is described in Table 1.
Fibrinogen gamma-A chain precursor
Fibrinogen gamma-A chain precursor was observed to
gradually increase along with the progression of disease
and showed the highest expression in group 3. The clinical
feature of group 3 is characterized by endstage of demen-
tia symptoms includingseverely impaired memory and
cognition, and devastated personal, whichresult in totally
dependent activities of daily living. The two spots were
found in all five patients and the molecular weight was
about 50 kDa. A pI of 5.6 was also noted, and confirmed
a very high reproducibility in a repeated experiment (Fig-
ure 3).
Discussion
The diagnosis of AD usually relies on excluding other dis-
orders with similar clinical features. To facilitate an early
diagnosis, additional diagnostic tools related to causes of
neuronal degeneration would be of great interest [15].
Such molecules that have been shown to be associated
with AD are free radicals and oxidative stress promoting
molecules, proinflammatory cytokines and neurotoxic
agents [16]. Most of these biomarker molecules are stud-
ied in the blood and may not reflect central pathologic
processes occurring in the brain of patients with AD.
Therefore, CSF is a more suitable biological fluid for study
of biomarker molecules in AD [17,18]. Of the many
potential areas for study of CSF, the field of proteomics is
especially well suited for discovery of biomarkers in CSF;
this is because proteins are abundant in CSF [15,19].
Proteomics has emerged in the last few years as a multidis-
ciplinary and technology-driven science that focuses on
proteomes: the complex of proteins expressed in biologi-
cal systems, their structures, interactions and post-transla-
tional modifications. In particular, proteomics examines
changes in protein levels and other protein alterations
that result from or foster specific diseases, or are affected
by various external factors, such as toxic agents.
The combination of immunoassays and proteomic meth-
ods reveals that CSF proteins express differential protein
patterns in AD, frontotemporal dementia (FTD), and PD
patients; these findings suggest divergent underlying
pathophysiological mechanisms and neuropathological
changes underlying these diseases.
Potential biomarkers with pathophysiologic significance
have been studied in the field of AD research with some
success, especially in the area of genetic markers (apolipo-
protein E epsilon4 allele), neuroimaging, and cerebrospi-
nal fluid markers (Aβ42 and tau). Of these, results using
proteomics combined with immunochemical studies are
the most abundant. To date, combined clinical examina-
tions and measurement of the biochemical markers (β-
Table 1: Identified CSF proteins particularly expressed in spots
Accession No. Protein Mascot score* Matched peptides Sequence coverage† Protein pI Protein MW (kDa)
P02679 Fibrinogen gamma-A chain 
precursor
80 20 44.9% 5.70 50.092
*Total MASCOT score: sum of individual matched peptide scores
† Percentage amino acid (AA) sequence coverage
Two-dimensional gel electrophoresis gel image using a CSF  sample from an AD patient Figure 2
Two-dimensional gel electrophoresis gel image using 
a CSF sample from an AD patient. Spots that were 
found to particularly expressed spots are arrow marked. 
These spots identified by fibrinogen gamma-A chain precur-
sor. The identified spots had a molecular weight of about 50 
kDa and a pI of 5.6.BMC Neurology 2007, 7:14 http://www.biomedcentral.com/1471-2377/7/14
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amyloid and tau) in CSF have become valuable diagnostic
tools for predicting more than 80% of AD cases [20].
Other proteins known to be associated with AD pathology
are apolipoprotein E (apo E) and synaptic proteins which
have been studied by immunoassays [16]. Other candi-
date CSF biomarkers include: ubiquitin [21], NF protein
[22], GAP43 (neuromodulin) [4,23,24], NTP, and AD7c
protein [25-27]. An increasing number of studies suggest
that supplementary use of these CSF markers preferably in
combination, adds to the accuracy of AD diagnosis [20].
Fibrinogen gamma chain (FGG) is the gamma compo-
nent of fibrinogen, a blood-borne glycoprotein comprised
of three pairs of non-identical polypeptide chains. FGG A
precursor is one of the transcript variant isoforms due to
alternative splicing [28].
The functional features of the FGG include participation
in fibrin polymerization and cross-linking, the initiation
of fibrinolysis, a role in binding and regulating factor XIII
activity, high affinity binding sites for integrin of platelets,
leukocyte, and a role in mediating thrombin binding to
fibrin, an inhibitory function originally termed 'anti-
thrombin I' [29].
It is well known that hemostatic factors and inflammatory
proteins are closely related to atherosclerosis and cardio-
vascular risk [30,31]. An additional hypothesis is that
these factors might be related to vascular dementia. There
are many reports that have discussed this relationship
[32]. However, there is limited evidence, and a paucity of
information, on hemostatic markers for AD. Moreover,
although there are reports on the association of AD with
fibrinogen in blood [33,34], there is no information of
such an association in CSF.
In our study, fibrinogen gamma-A chain precursor was
found to be increased in expression in both MCI and AD
patients compared to normal controls. This expression
was more prominent in AD patients than in both the nor-
mal controls and the MCI group, and appeared to be
related to the severity of dementia. Although we cannot
explain the actual relationship between FGG and AD at
this point in time, these findings suggest that activated
fibrinogen gamma-A chain precursor may be an impor-
tant marker for the linear progression of MCI to AD and
an important factor in the severity of AD. As regards the
potential use for predicting AD development, a longitudi-
nal analysis on MCI subjects is needed to verify the con-
version to AD.
However, it can not be excluded that increased levels of
FGG may be due to increased blood levels and/or
increased permeability across the blood-CSF barrier. Both
factors may influence the CSF FGG levels and thereby may
cause the differences seen between AD and controls. Fur-
ther studies will have to consider these putative factors to
ensure specificity of the present findings.
Conclusion
In conclusion we present that activated fibrinogen
gamma-A chain precursor may be an important marker
for the progression of MCI to AD and an important factor
in the severity of AD. Further study is needed to confirm
these findings and to improve the understanding of the
relationship between FGG, mild cognitive impairment
and AD.
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Differentially expressed spots of fibrinogen gamma-A chain  precursor Figure 3
Differentially expressed spots of fibrinogen gamma-A 
chain precursor. Shown (arrow marked) is the increase in 
expression pattern according to progression of disease. The 
findings were confirmed on a repeat experiment.BMC Neurology 2007, 7:14 http://www.biomedcentral.com/1471-2377/7/14
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